🚀
Enjoy a 7-Day Free Trial Thru Apr 25, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Merus NV (NAS:MRUS)
News
Merus NV
NAS
:MRUS (Netherlands) Â
$ 40.47
-0.58 (-1.41%)
04:00 PM EST
P/E:
At Loss
P/B:
6.57
Market Cap:
$ 2.38B
Enterprise V:
$ 2.07B
Volume:
243.10K
Avg Vol (2M):
575.50K
Warning! GuruFocus detected 2 Severe warning signs with MRUS.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
243.10K
Market Cap $:
2.38B
PE Ratio:
At Loss
Avg Vol (2M):
575.50K
Enterprise Value $:
2.07B
PB Ratio:
6.57
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocks™
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Merus NV (NAS:MRUS) Stock News, Headlines & Updates
Merus NV Stock News from GuruFocus
Total 118
1
2
3
Feb 08, 2024
Merus NV Business Update Transcript
GuruFocus Research
•
9:11pm
Merus NV at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus Research
•
9:10pm
Merus NV at Citi BioPharma Conference Transcript
GuruFocus Research
•
9:10pm
Merus NV at Jefferies Healthcare Conference Transcript
GuruFocus Research
•
9:10pm
Merus NV Investor Call Transcript
GuruFocus Research
•
9:10pm
Merus NV at Citi Virtual Oncology Leadership Summit Transcript
GuruFocus Research
•
9:10pm
Merus NV at SVB Securities Global Biopharma Conference (Virtual) Transcript
GuruFocus Research
•
9:10pm
Merus NV at Stifel Healthcare Conference Transcript
GuruFocus Research
•
9:10pm
Merus NV MCLA-129 Call Transcript
GuruFocus Research
•
9:10pm
Merus NV and ORIC Pharmaceuticals Inc at Citi BioPharma Conference Transcript
GuruFocus Research
•
9:10pm
Merus NV at Jefferies Healthcare Conference Transcript
GuruFocus Research
•
9:09pm
Merus NV Interim Clinical Data Call Transcript
GuruFocus Research
•
9:09pm
Merus NV Annual Shareholders Meeting Transcript
GuruFocus Research
•
9:09pm
Merus NV at Needham Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
9:09pm
Merus NV at SVB Leerink Global Healthcare (Virtual) Transcript
GuruFocus Research
•
9:09pm
Merus NV at Citi Immuno-Oncology Summit (Virtual) Transcript
GuruFocus Research
•
9:09pm
Merus NV at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
GuruFocus Research
•
9:09pm
Merus NV to Discuss the Zeno Clinical Data and Provide a Program Update - Corporate Call Transcript
GuruFocus Research
•
9:09pm
Merus NV to Present and Poster on MCLA-128 and MCLA-129 Programs - Corporate Call Transcript
GuruFocus Research
•
9:09pm
Merus NV at Cowen Health Care Conference Transcript
GuruFocus Research
•
9:09pm
Nov 26, 2023
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
GlobeNewswire
•
11:00am
Nov 01, 2023
Merus to Participate in Upcoming Investor Conferences
Marketwired
•
7:00am
Oct 23, 2023
Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
Marketwired
•
7:00am
Oct 16, 2023
Merus Announces Business Update Conference Call
GlobeNewswire
•
11:00pm
Merus Announces Business Update Conference Call
Marketwired
•
7:00pm
Oct 06, 2023
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
Marketwired
•
9:00am
Sep 07, 2023
Merus NV (MRUS): A Deep Dive into Its Overvalued Status
GuruFocus Research
•
5:36pm
Aug 31, 2023
Merus to Participate in Upcoming Investor Conferences
Marketwired
•
7:00am
Aug 10, 2023
Merus Announces Pricing of Public Offering of Common Shares
GlobeNewswire
•
11:00pm
Merus Announces Pricing of Public Offering of Common Shares
Marketwired
•
9:00pm
Aug 09, 2023
Merus N.V. Announces Proposed Public Offering of Common Shares
Marketwired
•
4:00pm
Aug 07, 2023
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
Marketwired
•
4:00pm
Jul 28, 2023
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
Marketwired
•
7:00am
Jul 05, 2023
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
Marketwired
•
4:00pm
Jun 29, 2023
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
GlobeNewswire
•
5:00pm
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
Marketwired
•
4:00pm
Jan 08, 2023
Merus Provides 2023 Outlook
Stock market mentor
•
8:00am
Nov 09, 2022
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
Value_Insider
•
7:00am
Oct 26, 2022
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
Value_Insider
•
3:00am
Sep 01, 2022
Merus to Participate in a Panel Discussion at Citi's 17th Annual BioPharma Conference
Ds***
•
8:00am
Total 118
1
2
3
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news